Related Experiment Video
Updated: Aug 13, 2026
06:51
Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases
Published on: December 9, 2022
Oxytocin Mitigates VEGF Expression in Differentiated RPE cells - A Novel Therapeutic Approach for Diabetic
Daira Yepez1, Cristian Mercado2, Gabriel Ordonez1
1Department of Neuroscience, The University of Texas Rio Grande Valley School of Medicine, Edinburg, Texas, USA.
Biomedical & Translational Science
|August 12, 2026
Summary
Oxytocin (OXT) may offer a new therapeutic approach for diabetic retinopathy (DR). This study found OXT reduces vascular endothelial growth factor (VEGF) secretion, a key driver of DR.
Area of Science:
- Ophthalmology
- Endocrinology
- Molecular Biology
Background:
- Diabetic retinopathy (DR) is a major cause of vision loss.
- Current anti-VEGF therapies for DR have limitations, including repeated administration and variable efficacy.
- Oxytocin (OXT), a neuropeptide, shows potential for metabolic and vascular regulation.
Purpose of the Study:
- To investigate the cellular and molecular mechanisms by which OXT inhibits vascular endothelial growth factor (VEGF).
- To explore OXT as a potential early-stage therapeutic intervention for diabetic retinopathy.
Main Methods:
- In vitro experiments using ARPE-19 cells to measure VEGF secretion.
- Dose- and time-dependent analysis of OXT's effect on VEGF.
- In vivo studies in animal models examining OXT and VEGF reduction.
Main Results:
- Oxytocin (OXT) significantly reduced VEGF secretion from ARPE-19 cells.
- The reduction in VEGF secretion was dose- and time-dependent.
- In vivo studies corroborated OXT's ability to reduce VEGF levels.
Conclusions:
- Oxytocin (OXT) demonstrates a clear inhibitory effect on VEGF secretion.
- OXT shows promise as an upstream therapeutic agent for early-stage diabetic retinopathy.
- Further research into OXT's molecular mechanisms is warranted for DR treatment development.
